Research programme: Sirtuin modulators - Lmito Therapeutics
Latest Information Update: 03 Feb 2023
At a glance
- Originator Lmito Therapeutics
- Class
- Mechanism of Action Sirtuin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 30 Dec 2022 Early research in Metabolic disorders in South Korea (unspecified route) (Lmito Therapeutics pipeline, December 2022)